Mirum Drug Patent Portfolio

Mirum owns 1 orange book drug protected by 9 US patents Given below is the list of Mirum's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12296050 Pharmaceutical compositions comprising maralixibat and uses thereof 05 Oct, 2043
Active
US11229647 Methods for treating cholestasis 12 Feb, 2040
Active
US11497745 Methods for treating cholestasis 12 Feb, 2040
Active
US11918578 Methods for treating cholestasis 12 Feb, 2040
Active
US10512657 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases 26 Oct, 2032
Active
US11229661 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases 26 Oct, 2032
Active
US11376251 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases 26 Oct, 2032
Active
US12350267 Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases 26 Oct, 2032
Active
US11260053 Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions 26 May, 2031
Active


Given below is the list of recent legal activities going on the following drug patents of Mirum.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 27 Aug, 2025 US11260053
Payment of Maintenance Fee, 4th Year, Large Entity 24 Jul, 2025 US11229661
Payment of Maintenance Fee, 4th Yr, Small Entity 24 Jul, 2025 US11229647
Recordation of Patent Grant Mailed 15 Jul, 2025 US12350267
Email Notification 08 Jul, 2025 US12350267
Mail Patent eGrant Notification 08 Jul, 2025 US12350267
Patent Issue Date Used in PTA Calculation 08 Jul, 2025 US12350267
Recordation of Patent eGrant 08 Jul, 2025 US12350267
Patent eGrant Notification 08 Jul, 2025 US12350267
Email Notification 26 Jun, 2025 US12350267
Issue Notification Mailed 25 Jun, 2025 US12350267
Dispatch to FDC 21 May, 2025 US12350267
Application Is Considered Ready for Issue 21 May, 2025 US12350267
Recordation of Patent Grant Mailed 20 May, 2025 US12296050
Issue Fee Payment Received 20 May, 2025 US12350267


Mirum's Family Patents

Mirum drugs have patent protection in a total of 18 countries. It's US patent count contributes only to 31.2% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Mirum Drug List

Given below is the complete list of Mirum's drugs and the patents protecting them.


1. Livmarli

Livmarli is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12296050 Pharmaceutical compositions comprising maralixibat and uses thereof 05 Oct, 2043
(17 years from now)
Active
US11229647 Methods for treating cholestasis 12 Feb, 2040
(13 years from now)
Active
US11497745 Methods for treating cholestasis 12 Feb, 2040
(13 years from now)
Active
US11918578 Methods for treating cholestasis 12 Feb, 2040
(13 years from now)
Active
US10512657 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases 26 Oct, 2032
(6 years from now)
Active
US11229661 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases 26 Oct, 2032
(6 years from now)
Active
US11376251 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases 26 Oct, 2032
(6 years from now)
Active
US12350267 Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases 26 Oct, 2032
(6 years from now)
Active
US11260053 Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions 26 May, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Livmarli's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Mirum News

Mirum receives second FDA approval for Livmarli, a drug for treating PFIC, a rare liver disease

13 Mar, 2024

See More